Pedro Besada

Vigo, GA 36213, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Biological Potential and Physicochemical Properties of Ionic Liquids Bioinspired by Carboxylic Acids: A Review.

Biological Potential and Physicochemical Properties of Ionic Liquids Bioinspired by Carboxylic Acids: A Review.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 25, 2026

Stilbene-pyridazinone hybrids: design, synthesis and in vitro antiplatelet activity screening.

Stilbene-pyridazinone hybrids: design, synthesis and in vitro antiplatelet activity screening.

Journal: Bioorganic chemistry

Published: April 09, 2024

Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents.

Novel Phthalazin-1(2H)-One Derivatives Displaying a Dithiocarbamate Moiety as Potential Anticancer Agents.

Journal: Molecules (Basel, Switzerland)

Published: October 31, 2022

Novel Pyridazin-3(2H)-one-Based Guanidine Derivatives as Potential DNA Minor Groove Binders with Anticancer Activity.

Novel Pyridazin-3(2H)-one-Based Guanidine Derivatives as Potential DNA Minor Groove Binders with Anticancer Activity.

Journal: ACS medicinal chemistry letters

Published: November 11, 2021

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.

Journal: Biomolecules

Published: October 30, 2021

Pyridazinones containing dithiocarbamoyl moieties as a new class of selective MAO-B inhibitors.

Pyridazinones containing dithiocarbamoyl moieties as a new class of selective MAO-B inhibitors.

Journal: Bioorganic chemistry

Published: April 27, 2021

Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.

Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson's disease therapy.

Journal: Bioorganic chemistry

Published: May 22, 2020

Novel compounds of hybrid structure pyridazinone-coumarin as potent inhibitors of platelet aggregation.

Novel compounds of hybrid structure pyridazinone-coumarin as potent inhibitors of platelet aggregation.

Journal: Future medicinal chemistry

Published: September 21, 2019

Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry.

Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry.

Journal: European journal of medicinal chemistry

Published: July 17, 2018

Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.

Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.

Journal: European journal of medicinal chemistry

Published: June 02, 2017

Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.

Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.

Journal: Molecular diversity

Published: April 20, 2015

New platelet aggregation inhibitors based on pyridazinone moiety.

New platelet aggregation inhibitors based on pyridazinone moiety.

Journal: European journal of medicinal chemistry

Published: November 07, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026